Cancer immunotherapy according to GARP

Immunotherapy Cancer, like microbes, can adapt to become resistant to a single therapy, making combination therapies the approach of choice. Complementary therapies that decrease immunosuppression may boost the efficacy of immunotherapies. Rachidi et al. found that targeting platelets improved adoptive T cell therapy of multiple cancers in mice. Transforming growth factor β (TGFβ) from platelets decreased T cell function, largely through the expression of the TGFβ docking receptor, GARP (glycoprotein A repetitions predominant). Thus, combining immunotherapy with platelet inhibitors may improve cancer therapy. Sci. Immunol. 2 , eaai7911 (2017).